ABT
Abbott Laboratories · Healthcare · Medical - Devices
Momentum inputs (comparable managers): holder breadth 0.0% · share flow -2.3% · net new positions 0.0% · formula
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 4 | 0 | 8.65M | $848.35M | n/a | −1 |
| Q2 2026 | 180 | 0 | 1.09B | $98.86B | +5 | −6 |
| Q1 2026 | 184 | +3 | 1.11B | $114.25B | +7 | −5 |
| Q4 2025 | 180 | +2 | 1.17B | $146.24B | +3 | n/a |
| Q3 2025 | 24 | 0 | 623.34M | $83.47B | +1 | −2 |
| Q2 2025 | 22 | 0 | 527.92M | $71.78B | +1 | −1 |
| Q1 2025 | 19 | 0 | 196.20M | $26.01B | +1 | −1 |
| Q4 2024 | 19 | -1 | 182.48M | $20.63B | n/a | −1 |
| Q3 2024 | 19 | 0 | 108.33M | $12.33B | +1 | −1 |
| Q2 2024 | 19 | n/a | 110.87M | $11.51B | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Geode Capital Management ✦ (passive) | 34.90M | +1.4% | $3.96B | 0.3% | ▲ Add | 2 | SEC ↗ ×2 |
| 2 | Wellington Management ✦ | 25.81M | +1.1% | $2.94B | 0.5% | ▲ Add | 2 | SEC ↗ ×8 |
| 3 | Norges Bank ✦ (passive) | 20.28M | -0.4% | $2.31B | 0.3% | ▼ Trim | 2 | SEC ↗ |
| 4 | Fisher Asset Management ✦ | 11.10M | +5.6% | $1.27B | 0.5% | ▲ Add | 2 | SEC ↗ |
| 5 | T. Rowe Price ✦ | 4.05M | -0.3% | $461.80M | 0.1% | ▼ Trim | 2 | SEC ↗ ×2 |
| 6 | Arrowstreet Capital ✦ | 2.53M | +10.0% | $288.47M | 0.2% | ▲ Add | 2 | SEC ↗ |
| 7 | Two Sigma Investments ✦ | 1.93M | -19.0% | $219.65M | 0.5% | ▼ Trim | 2 | SEC ↗ |
| 8 | Adage Capital Partners ✦ | 1.49M | -9.9% | $169.88M | 0.3% | ▼ Trim | 2 | SEC ↗ |
| 9 | Capital World Investors ✦ | 1.34M | New | $152.44M | 0.0% | New | 1 | SEC ↗ |
| 10 | AQR Capital Management ✦ | 1.33M | +52.4% | $149.80M | 0.2% | ▲ Add | 2 | SEC ↗ ×3 |
| 11 | Millennium Management ✦ | 1.27M | -45.3% | $145.29M | 0.1% | ▼ Trim | 2 | SEC ↗ |
| 12 | PRIMECAP Management ✦ | 919.46K | -1.2% | $104.83M | 0.1% | ▼ Trim | 2 | SEC ↗ |
| 13 | Bridgewater Associates ✦ | 707.62K | -57.6% | $80.68M | 0.5% | ▼ Trim | 2 | SEC ↗ |
| 14 | Citadel Advisors ✦ | 361.75K | -63.2% | $41.24M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 15 | Marshall Wace ✦ | 123.23K | -43.0% | $14.05M | 0.0% | ▼ Trim | 2 | SEC ↗ ×2 |
| 16 | D. E. Shaw & Co. ✦ | 96.48K | -90.5% | $11.00M | 0.0% | ▼ Trim | 2 | SEC ↗ ×2 |
| 17 | Gotham Asset Management ✦ | 40.30K | +16.1% | $4.60M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 18 | GAMCO Investors ✦ | 22.57K | -1.7% | $2.57M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 19 | Dodge & Cox ✦ | 17.86K | 0.0% | $2.04M | 0.0% | Held | 2 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| Capital World Investors | $152.44M | 0.0% |
Exited
| Renaissance Technologies | $162.35M | was 0.3% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 3,058 holders, 1.35B shares, $133.47B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 27 sh · $2,958
Officer, Director · 180.30K sh · $20.95M
Officer, Director · 218.53K sh · $25.26M
Officer · 5.85K sh · $642,506
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology